A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME)

Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME)

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2016

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Chronic fatigue syndrome; Encephalomyelitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Hemispherx Biopharma
  • Most Recent Events

    • 31 Oct 2016 Retrospective sub-group analysis results presented at the 12th International IACFS/ME Research and Clinical Conference, as per Hemispherx Biopharma media release.
    • 31 Oct 2016 Retrospective sub-group analysis results published in Hemispherx Biopharma media release.
    • 31 Oct 2016 Primary endpoint (Exercise tolerance) has been met, as per Hemispherx Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top